Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251465 | 0.95 | HSD17B2 (0.37) | HSD17B2BRD4CREBBPP2RX7NTRK1 | |
| SCHEMBL24251382 | 0.89 | HSD17B2 (0.38) | HSD17B2BRD4CREBBPNTRK1TRPV1 | |
| SCHEMBL24251567 | 0.87 | P2RX7 (0.38) | HSD17B2BRD4CREBBPP2RX7NTRK1 | |
| SCHEMBL23355416 | 0.86 | BRD4 (0.40) | HSD17B2BRD4CREBBPNTRK1TRPV1 | |
| SCHEMBL24251354 | 0.86 | BRD4 (0.40) | HSD17B2BRD4CREBBPNTRK1TRPV1 | |
| SCHEMBL24251449 | 0.85 | BRD4 (0.38) | HSD17B2BRD4CREBBPP2RX7NTRK1 | |
| SCHEMBL24251500 | 0.85 | BRD4 (0.37) | HSD17B2BRD4CREBBPNTRK1TRPV1 | |
| SCHEMBL24251501 | 0.83 | BRD4 (0.38) | HSD17B2BRD4CREBBPP2RX7NTRK1 | |
| SCHEMBL24251429 | 0.82 | HSD17B2 (0.36) | HSD17B2BRD4CREBBPNTRK1TRPV1 | |
| SCHEMBL24251467 | 0.82 | BRD4 (0.36) | HSD17B2BRD4CREBBPP2RX7NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | SDHA, PAH, PIGS | HSD17B2 909/4885BRD4 2177/4885CREBBP 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.